Danaher Corporation (DHR)vsEXACT Sciences Corporation (EXAS)
DHR
Danaher Corporation
$200.14
-0.19%
HEALTHCARE · Cap: $140.97B
EXAS
EXACT Sciences Corporation
$104.91
0.00%
HEALTHCARE · Cap: $20.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 673% more annual revenue ($25.11B vs $3.25B). DHR leads profitability with a 16.0% profit margin vs -6.4%. DHR earns a higher WallStSmart Score of 66/100 (B-).
DHR
Strong Buy66
out of 100
Grade: B-
EXAS
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.9%
Fair Value
$118.49
Current Price
$200.14
$81.65 premium
Intrinsic value data unavailable for EXAS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 59.7% YoY
Large-cap with strong market position
Reasonable price relative to book value
Generating 1.3B in free cash flow
Revenue surging 23.1% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
ROE of 7.6% — below average capital efficiency
Trading at 8.3x book value
0.0% earnings growth
ROE of -8.7% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on EPS Growth, Market Cap, Price/Book. Profitability is solid with margins at 16.0% and operating margin at 19.8%. PEG of 1.23 suggests the stock is reasonably priced for its growth.
Bull Case : EXAS
The strongest argument for EXAS centers on Revenue Growth. Revenue growth of 23.1% demonstrates continued momentum.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Return on Equity.
Bear Case : EXAS
The primary concerns for EXAS are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
DHR profiles as a mature stock while EXAS is a growth play — different risk/reward profiles.
EXAS carries more volatility with a beta of 1.44 — expect wider price swings.
EXAS is growing revenue faster at 23.1% — sustainability is the question.
DHR generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (66/100 vs 32/100), backed by strong 16.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
EXACT Sciences Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Exact Sciences Corporation offers cancer screening and diagnostic test products in the United States and internationally. The company is headquartered in Madison, Wisconsin.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?